La cadena de opciones muestra datos clave de las opciones de acciones de X4 Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para X4 Pharmaceuticals..

X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa, Cadena de Opciones

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

WIIM

TOPW

Top Win International shares are trading higher after the company announced it launched a digital assets treasury strategy to participate in Asia's growing web3 ecosystem.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.0900</td>
<td align="right">0.63</td>
<td align="right">0.48</td>
<td>35.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.3200</td>
<td align="right">0.33</td>
<td align="right">0.40</td>
<td>2.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.4899</td>
<td align="right">0.32</td>
<td align="right">0.37</td>
<td>603</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.4300</td>
<td align="right">0.80</td>
<td align="right">0.37</td>
<td>4.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.8800</td>
<td align="right">0.27</td>
<td align="right">0.31</td>
<td>67.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.6000</td>
<td align="right">0.44</td>
<td align="right">0.30</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.3500</td>
<td align="right">0.07</td>
<td align="right">0.13</td>
<td>69.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">101.2200</td>
<td align="right">0.13</td>
<td align="right">0.12</td>
<td>28.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.7500</td>
<td align="right">0.30</td>
<td align="right">0.12</td>
<td>120.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.2000</td>
<td align="right">0.06</td>
<td align="right">0.07</td>
<td>11.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.5200</td>
<td align="right">0.03</td>
<td align="right">0.07</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 16, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday.
Shares of Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results, issued second-quarter guidance below estimates, and <a href="https://www.benzinga.com/quote/GLOB">cut its FY25 guidance</a>.
Globant reported quarterly earnings of $1.50 per share which missed the analyst consensus estimate of $1.58 per share. The company reported quarterly sales of $611.09 million which missed the analyst consensus estimate of $621.38 million.
Globant shares dipped 26.2% to $98.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) dipped 22.1% to $45.52 in pre-market trading after the company issued FY26 sales guidance below estimates.</li>
<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) declined 15.2% to $17.94 in pre-market trading. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) fell 13.2% to $11.50 in pre-market trading after dipping 67% on Thursday.</li>
<li>BRF S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>) dropped 11.1% to $3.19 in pre-market trading after gaining 3% on Thursday.</li>
<li>Lithium Americas Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAC#NYSE">LAC</a>) dipped 10.8% to $2.82 in pre-market trading as the company filed for mixed shelf of up to $1.0 billion.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) fell 10.1% to $1.33 in pre-market trading after the company reported first-quarter financial results and missed its EPS and revenue estimates.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 5.8% to $164.65 in pre-market trading. Applied Materials reported better-than-expected earnings for its second quarter, while sales missed estimates. Applied Materials said it expects third-quarter revenue of $7.2 billion, plus or minus $500 million, versus estimates of $7.19 billion. The company expects third-quarter adjusted earnings to be between $2.15 and $2.55 per share, versus estimates of $2.32 per share.</li>
<li>Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) fell 3.7% to $223.68 in pre-market trading. Take-Two reported fourth-quarter net bookings of $1.58 billion, up 17% year-over-year. The total beat a Street consensus estimate of $1.55 billion according to data from Benzinga Pro. The company said it expects first quarter net bookings to be in a range of $1.25 billion to $1.30 billion. The company guides for full fiscal-year net bookings to be in a range of $5.90 billion to $6.00 billion.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45435278/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

News

Markets

Trading Ideas

AMAT

ARAI

BRFS

DOCS

GLOB

KULR

TTWO

TVTX

Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Bon Natural Life Limited shares are trading higher after the company announced a cooperation agreement with Beijing's Huahai Keyuan, who will serve as an exclusive sales partner.

The deal expands the current slate with new co-produced shows and continues the distribution of Bloomberg's full catalog of podcasts including newly launched "Levittown" and "Everybody's Business"

IHRT

iHeartMedia Extends Multiyear Podcast Partnership With Bloomberg Media

JP Morgan analyst Mark Strouse maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $430 to $460.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on GE Vernova, Raises Price Target to $460

<a href="https://www.coinbase.com/blog/coinbase-partners-with-webull-pay-to-power-crypto-experience" title="https://www.coinbase.com/blog/coinbase-partners-with-webull-pay-to-power-crypto-experience">https://www.coinbase.com/blog/coinbase-partners-with-webull-pay-to-power-crypto-experience</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

BULL

COIN

Coinbase Partners with Webull Pay to Power Crypto Experience

Occidental And ADNOC's XRG Evaluate Joint Venture To Develop Direct Air Capture Hub

SMCI

Super Micro Computer Enters Into Strategic Partnership Under MOU With DataVolt To Build Hyperscale AI Campuses Initially In Kingdom Of Saudi Arabia

INZY

Inozyme shares are trading higher after the company announced BioMarin will acquire the company for about $270 million.

JP Morgan analyst Harlan Sur maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Overweight and lowers the price target from $240 to $210.

JP Morgan Maintains Overweight on Applied Mat, Lowers Price Target to $210

- Treatment with ELEVIDYS for Duchenne muscular dystrophy resulted in mean protein expression of 93.87% as measured by western blot in study participants (n=6)
- Safety profile consistent with prior studies of ELEVIDYS and real-world experience

Biotech

General

SRPT

Sarepta Therapeutics Shares Safety Results From ENDEAVOR Study In 2-Year-Old Participants

SoFi's Rising Stars Program Provides Post-Secondary Students with Financial Skills and Resources They Need to Succeed: Financial Education, 1:1 Coaching, Grants, and Resources to Start Investing Early
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sofi.com%2F&amp;esheet=54255917&amp;newsitemid=20250516502271&amp;lan=en-US&amp;anchor=SoFi+Technologies%2C+Inc.&amp;index=1&amp;md5=3cc8f6a151ed26659557d2f9b94039a4">SoFi Technologies, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) has teamed up with five-time GRAMMY&#xAE; Award nominated, multiple ACM and CMA Award winning, multiplatinum songwriter, producer, and author Kelsea Ballerini and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tnachieves.org%2F&amp;esheet=54255917&amp;newsitemid=20250516502271&amp;lan=en-US&amp;anchor=tnAchieves&amp;index=2&amp;md5=14e56c6b22f558b6d510885ec4cdc031">tnAchieves</a>, a nationally recognized nonprofit dedicated to college access and success, to launch the Rising Stars Program. This $2 million initiative is aimed at helping the next generation of Tennessee students achieve financial independence. SoFi will provide tnAchieves with over $500,000 in grants to expand its COMPLETE program. SoFi's contributions will fund students' 1:1 coaching and financial support as they prepare for a high-skill, high-wage career, as well as a specialized financial readiness curriculum for the 60,000 students across their programs. In addition, to help people start investing early, SoFi is offering every Tennessee resident between 18-24 the opportunity to receive a minimum of $5 in stock of their choosing, at no cost, with a chance to receive up to $1,000 in stock – all with no minimum deposit or fees required.

SOFI

SoFi Partners With Kelsea Ballerini And tnAchieves To Invest $2M For Tennessee's Next Gen Students To Achieve Financial Independence

<ul>
<li>Significant functional benefits for 8- and 9-year-olds with Duchenne in Part 2 of the EMBARK study, contributing to the evidence of stabilization or slowing of disease progression in later childhood when muscle weakness typically progresses</li>
<li>Statistically significant differences were observed on all key endpoints including 4.75 points (P=0.0026) on North Star Ambulatory Assessment (NSAA), 6.87 seconds in time-to-rise (TTR) from the floor (P=0.0010), and 4.76 seconds in 10-meter walk/run (10MWR) (P=0.0097) compared to a well-matched external control cohort
<ul>
<li>Five abstracts, including two oral presentations at American Society of Gene &amp; Cell Therapy Conference, span Sarepta's portfolio of approved and pipeline therapies across Duchenne and limb-girdle muscular dystrophy</li>
</ul>
</li>
</ul>

Events

Sarepta Therapeutics Presents Part 2 EMBARK Data At American Society of Gene & Cell Therapy Conference

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram Announces Development Of A Neural Network-Based Quantum-Assisted Unsupervised Data Clustering Technology

Bon Natural Life Limited Announces Cooperation Agreement With Beijing Huahai Keyuan, Which Wil Serve As Exclusive Sales Partner Of BON's Postbiotic Hypoglycemic Ingredient Product Series

Analysts' ratings for Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) over the last quarter vary from bullish to bearish, as provided by 21 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $132.19, a high estimate of $170.00, and a low estimate of $75.00. Experiencing a 5.74% decline, the current average is now lower than the previous average price target of $140.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1747400459_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Twilio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Stephen Bersey</td>
<td>HSBC</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$122.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$108.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$144.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Twilio. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Twilio compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Twilio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Twilio's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TWLO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Twilio analyst ratings.</a>
<h2>Get to Know Twilio Better</h2>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
<h3>Financial Milestones: Twilio's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Twilio's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 11.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Twilio's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Twilio's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.25%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Twilio's ROA excels beyond industry benchmarks, reaching 0.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Twilio's debt-to-equity ratio is below the industry average at 0.14, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TWLO

What 21 Analyst Ratings Have To Say About Twilio

23 analysts have expressed a variety of opinions on Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">13</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Netflix and provided 12-month price targets. The average target is $1171.87, accompanied by a high estimate of $1514.00 and a low estimate of $1000.00. This current average reflects an increase of 3.84% from the previous average price target of $1128.52. 
<img src="https://www.benzinga.com/files/images/story/2025/1747400446_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Netflix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1380.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$1350.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1175.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1070.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1222.00</td>
<td>$1210.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1126.00</td>
<td>$1126.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$1514.00</td>
<td>$1494.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1126.00</td>
<td>$1126.00</td>
</tr>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1140.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Michael Nathanson</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$850.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Netflix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Netflix compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Netflix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Netflix's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NFLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Netflix analyst ratings.</a>
<h2>Delving into Netflix's Background</h2>
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
<h3>Netflix's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Netflix showcased positive performance, achieving a revenue growth rate of 12.51% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Netflix's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 27.42%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Netflix's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Netflix's ROA excels beyond industry benchmarks, reaching 5.47%. This signifies efficient management of assets and strong financial health.
Debt Management: Netflix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NFLX

What 23 Analyst Ratings Have To Say About Netflix

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for NICE, revealing an average target of $210.08, a high estimate of $300.00, and a low estimate of $161.00. This current average represents a 10.05% decrease from the previous average price target of $233.54. 
<img src="https://www.benzinga.com/files/images/story/2025/1747400437_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of NICE by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$228.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$161.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Tavy Rosner</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$226.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$279.00</td>
<td>$315.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NICE. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NICE compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for NICE's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NICE's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NICE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NICE analyst ratings.</a>
<h2>Discovering NICE: A Closer Look</h2>
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. The company provides data analytics-based solutions through both a cloud platform and on-premises infrastructure. Within customer engagement, Nice's CXone platform delivers solutions focused on contact center software and workforce engagement management, or WEM. Contact center offerings include solutions for digital self-service, customer journey and experience optimization, and compliance. WEM products optimize call center efficiency, leveraging data and AI analytics for call volume forecasting and agent scheduling. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money laundering, and compliance solutions.
<h3>Financial Insights: NICE</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: NICE's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 15.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: NICE's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.79%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NICE's ROE excels beyond industry benchmarks, reaching 2.78%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.9%, the company showcases effective utilization of assets.
Debt Management: NICE's debt-to-equity ratio is below the industry average. With a ratio of 0.16, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NICE

Where NICE Stands With Analysts

Bright Horizons Family's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) short percent of float has risen 7.24% since its last report. The company recently reported that it has 928 thousand shares sold short, which is 1.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bright Horizons Family Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747400431_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bright Horizons Family has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bright Horizons Family's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bright Horizons Family's peer group average for short interest as a percentage of float is 4.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

BFAM

How Is The Market Feeling About Bright Horizons Family?

Press Releases

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Health Care

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Earnings

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host  Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

Comments

X4 Pharmaceuticals

X4 Pharmaceuticals (XFOR) Opciones

X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL